These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 540521

  • 1. Xanthinol nicotinate in the management of leg ulcers associated with haemoglobinopathies.
    Afifi AM, Adnan M, Taha M, Amasha ME.
    Curr Med Res Opin; 1979; 6(5):309-13. PubMed ID: 540521
    [Abstract] [Full Text] [Related]

  • 2. Comparative effects of placebo and plain and slow-release tablets of xanthinol nicotinate on exercise tolerance in normal human subjects.
    Sharma PL.
    Int J Clin Pharmacol Biopharm; 1978 Jan; 16(1):19-21. PubMed ID: 631966
    [Abstract] [Full Text] [Related]

  • 3. [Bioavailability and tolerance of xanthinol nicotinate depot preparations. Comparison of a conventional 500 mg xanthinol nicotinate depot tablet with new 500 mg and 1 g depot tablets].
    von Schrader HW, Buscher G, Dierdorf D, Freytag A, Mügge H, Wolf D.
    Arzneimittelforschung; 1985 Jan; 35(9):1468-72. PubMed ID: 4084347
    [Abstract] [Full Text] [Related]

  • 4. [Clinical trial of xanthinol nicotinate in delayed form in the treatment of arteritis of the lower limbs].
    Niquet G, Dupont T.
    Lille Med; 1976 Jan; 21(1 suppl 1):13-5. PubMed ID: 1256225
    [No Abstract] [Full Text] [Related]

  • 5. [Drug therapy of hyperlipemia. Experiences with xanthinol nicotinate retard-capsules in a general practice].
    Klimm HD.
    Med Monatsschr; 1976 Apr; 30(4):178-80. PubMed ID: 958145
    [No Abstract] [Full Text] [Related]

  • 6. Acute effect of xanthinol nicotinate on the muscle clearance of 133Xenon.
    Szilvási I, Molnár G.
    Ther Hung; 1973 Apr; 21(3-4):114-6. PubMed ID: 4806418
    [No Abstract] [Full Text] [Related]

  • 7. [The observation of the influence of the unretarded form of xanthinol-niacinate (Complamine) in ulcus cruris venosum on the skin temperature of the lower extremities with the biochemical determination of the levels of the preparation (author's transl)].
    Resl V, Götzová, Vitous J.
    Cesk Dermatol; 1976 Dec; 51(6):389-93. PubMed ID: 1009598
    [No Abstract] [Full Text] [Related]

  • 8. The effects of nicotinic acid and xanthinol nicotinate on human memory in different categories of age. A double blind study.
    Loriaux SM, Deijen JB, Orlebeke JF, De Swart JH.
    Psychopharmacology (Berl); 1985 Dec; 87(4):390-5. PubMed ID: 3936095
    [Abstract] [Full Text] [Related]

  • 9. Xanthinol nicotinate in peripheral vascular disease.
    Davis E, Rozov H.
    Practitioner; 1975 Dec; 215(1290):793-8. PubMed ID: 772653
    [Abstract] [Full Text] [Related]

  • 10. Thermographical follow-up during treatment of chronic ulcerations with iontophoresis with xanthinol nicotinate.
    van der Kuy A, Aarts NJ.
    Bibl Radiol; 1975 Dec; (6):203-9. PubMed ID: 1180851
    [No Abstract] [Full Text] [Related]

  • 11. [Xanthinol nicotinate and bufenin hydrochloride in the treatment of gestosis].
    Cretti A, Jaworski S.
    Ginekol Pol; 1976 Aug; 47(8):909-16. PubMed ID: 971859
    [No Abstract] [Full Text] [Related]

  • 12. [Results of a long-term study on the therapeutic effectiveness of xanthinol nicotinate in chronic hepatopathies].
    Dohrmann RE, Kessel ME.
    Z Allgemeinmed; 1975 Sep 20; (26):1167-72. PubMed ID: 1226797
    [No Abstract] [Full Text] [Related]

  • 13. [Use of xanthinol nicotinate in patients with chronic ischemic heart disease].
    Sivkov II, Kukes VG, Borisov VG, Rudakov MA, Blistanova LS.
    Ter Arkh; 1977 Sep 20; 49(1):30-3. PubMed ID: 867235
    [No Abstract] [Full Text] [Related]

  • 14. [Therapy of hyperlipidemia with xanthinol nicotinate as opposed to low fat diet].
    Baumann J, Martschick R.
    Med Welt; 1982 Jan 29; 33(4):139-41. PubMed ID: 7062844
    [No Abstract] [Full Text] [Related]

  • 15. [Therapy of cerebrovascular insufficiency. A psychometric double-blind trial with a slow-release form of xantinol nicotinate (author's transl)].
    Brückner GW, Jansen W.
    MMW Munch Med Wochenschr; 1979 Jun 22; 121(25):861-4. PubMed ID: 111104
    [Abstract] [Full Text] [Related]

  • 16. [The effect of xanthinol nicotinate on the serum lipids and lipoproteins of patients with primary hyperlipoproteinemia Type IIb and IV].
    Haacke H, Parwaresch MR, Mäder C.
    Verh Dtsch Ges Inn Med; 1976 Jun 22; 82 Pt 1():829-32. PubMed ID: 1029294
    [No Abstract] [Full Text] [Related]

  • 17. [Lipids in pregnant patients with severe course of gestosis treated with xanthinol nicotinate and bufenin hydrochloride].
    Kuć A, Skrzydlewski Z.
    Ginekol Pol; 1976 Apr 22; 47(4):379-82. PubMed ID: 177335
    [No Abstract] [Full Text] [Related]

  • 18. [Rehabilitation course in patients with peripheral and coronary angio-organopathies. Studies with special reference to serum uric acid and cholesterol under xanthinol nicotinate].
    Mensen H.
    Ther Ggw; 1977 Oct 22; 116(10):1853-81. PubMed ID: 918880
    [No Abstract] [Full Text] [Related]

  • 19. [Changes in the oxidative glucose brain metabolism under long-term xantinol-nicotinate medication (author's transl)].
    Quadbeck H, Lehmann E.
    Arzneimittelforschung; 1978 Oct 22; 28(9):1531-2. PubMed ID: 582552
    [Abstract] [Full Text] [Related]

  • 20. [Human placental lactogen (HPL) levels in the maternal serum following long-term intake of xantinol nicotinate (Complamin Retard) (author's transl)].
    Sérey CT, Saling E.
    Z Geburtshilfe Perinatol; 1980 Aug 22; 184(4):283-9. PubMed ID: 7008399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.